As the number of antibody technology offerings has grown, differentiating each from the competition has taken on more importance. For Abgenix Inc., staying competitive means obtaining access to technologies that complement or enhance its antibody production platform, but not adding new platforms such as target discovery.

In the last two weeks, ABGX completed its acquisition of screening company ImmGenics Inc. (Vancouver, B.C.) for $77 million in stock and announced its acquisition of IntraImmune Therapies Inc. (Cambridge, Mass.) for $9 million in cash (see B2).